Description_x000D_ Application_x000D_ Ethosuximide has been used:_x000D_ • to confirm its effect on spike wave discharges (SWD) in rats_x000D_ • to examine its effects on spontaneous locomotion and anxiety-related thigmotaxis behaviours in zebrafish larvae of wild type_x000D_ • as a model drug for the treatment of epilepsy in vivo(4)_x000D_ Packaging_x000D_ 5, 100 g in glass bottle_x000D_ Biochem/physiol Actions_x000D_ Ethosuximide is an anticonvulsant drug and an antagonist for T-type calcium channel. It is known to prevent spike wave discharges, characterized in absence seizures._x000D_ Features and Benefits_x000D_ This compound is also offered as part of Sigma′s Library of Pharmacologically Active Compounds (LOPAC®1280), a biologically annotated collection of high-quality, ready-to-screen compounds. Click here to learn more._x000D_ This compound is featured on the Calcium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here._x000D_ This compound was developed by Pfizer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here._x000D_ Other Notes_x000D_ Tandem Mass Spectrometry data independently generated by Scripps Center for Metabolomics is available to view or download in PDF. E7138.pdf Tested metabolites are featured on Scripps Center for Metabolomics METLIN Metabolite Database. To learn more, visit sigma.com/metlin._x000D_ Legal Information_x000D_ LOPAC is a registered trademark of Sigma-Aldrich Co. LLC